Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Six months ended December 31, 2025 (Fiscal Year 2026 Q2)
Business Overview: A development-stage biopharmaceutical company focused on cancer treatments, specifically its lead product candidate PRP (a pro-enzyme formulation). The Company has no commercial revenue and relies on equity and debt financing to fund research and development (R&D) and operations. The Company is incorporated in Delaware with principal operations in Australia.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7,929,132) | $(784,493) |
| Net Loss Available to Common Stockholders | $(8,861,378) | $(784,493) |
| Net Cash Used in Operating Activities | $(2,938,207) | $(216,786) |
| Cash and Cash Equivalents (Ending) | $561,237 | $14,633 |
| Total Assets | $15,111,532 | $19,631,808 |
| Total Liabilities | $3,659,267 | $5,725,616 |
| Stockholders' Equity | $10,452,265 | $13,906,192 |
Debt and Liquidity: As of December 31, 2025, the Company held $561,237 in cash. Total current liabilities were $3,624,018, including $55,000 in convertible notes, $472,083 in related party loans, and $288,635 in warrant liabilities. The Company has an accumulated deficit of $134,482,898.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses surged to $8,328,298 for the six months ended December 31, 2025, compared to $504,172 in the prior year period. This increase was driven primarily by a $6.2 million rise in stock-based consulting expenses and a $1.3 million increase in general consulting, legal, and investor relations fees.
- Net Loss: Net loss increased significantly to $7.9 million from $0.8 million in the prior year, largely due to the spike in administrative expenses and a $932,246 deemed dividend related to Series C Preferred Stock issuance.
- Financing Activities: The Company raised approximately $4.3 million in net proceeds during the period, including $3.3 million from a common stock offering and $0.95 million from a Series C Preferred Stock private placement. This contrasts with the prior period where financing proceeds were significantly lower.
- Debt Reduction: The Company repaid significant portions of its promissory notes and convertible debt during the period, reducing notes payable from $543,312 (June 2025) to $0 (December 2025) and convertible notes from $537,921 to $55,000.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern for the next 12 months. The Company has no revenue, significant accumulated losses, and negative working capital. Continued operations depend on securing additional equity or debt financing.
- R&D Progress: The Company filed two provisional patents in December 2025 regarding treatments for resistant cancer and fibrosis. In January 2026, a provisional patent was filed for a fully synthetic recombinant version of PRP (Rec-PRP). Key research findings regarding PRP's impact on pancreatic cancer fibroblasts were published in Scientific Reports.
- Legal Proceedings: On December 9, 2025, the Company was sued by Helena Partners, Inc., alleging breach of an engagement agreement and seeking a $250,000 break fee plus a $15,000 deposit. The Company intends to vigorously defend the action.
- Internal Controls: The Company identified material weaknesses in internal controls over financial reporting, including a lack of written documentation and insufficient segregation of duties. Management plans to establish an audit committee and hire experienced accounting personnel to address these issues.
- Subsequent Events: In January 2026, the Company issued 2,000,000 shares of common stock upon conversion of Series C Preferred Stock and settled a $65,280 loan with Crown Bridge via an exchange agreement.
Investor Verification Checklist
- Cash Runway: Verify if the $561,237 cash balance is sufficient to cover the current burn rate given the "Going Concern" warning and lack of revenue.
- Debt Defaults: Confirm the status of the $55,000 convertible note and related party loans, noting that some loans were in default as of the balance sheet date.
- Legal Exposure: Monitor the outcome of the Helena Partners lawsuit regarding the $265,000 claim.
- Stock-Based Compensation: Review the sustainability of the $6.2 million increase in stock-based consulting expenses and the associated dilution from share issuances for services.
- Patent Valuation: Assess the commercial viability and regulatory pathway for the newly filed provisional patents (Rec-PRP and fibrosis treatments).